CDMO News
Excellos to Manufacture Galapagos’ CAR-T Therapy for U.S. Clinical Trial
Excellos Inc., a contract development and manufacturing organisation (CDMO) and member of Blood Centers of America (BCA), has been selected to manufacture Galapagos’ CAR-T cell therapy candidate, GLPG5101. The production will support the recently FDA-cleared ATALANTA-1 clinical study targeting relapsed
2 October 2024
Stay ahead of trends and best practices
